Ticker brief

FDMT

last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
10
authors 14d
5

No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.

Sentiment — last 14 days
daily mean sentiment, 2026-06-22 → 2026-07-02 · now -0.09 (−1 bearish … +1 bullish)
Who spoke5
authorgradetrader scoresignalsmean sent
@Stockspy1C+0.016-0.26
@Quantumup1C-1.951+0.00
@OzmosiHealthC·1+0.30
@BiopharmIQB·1+0.35
@Analytica_XB-1.081+0.25
Recent signals10of 10 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-07-02@Stockspy1-0.09Mentions liked biotechs and preference for med equipment/chemicals.·
2026-07-01@Analytica_X+0.25Watchlist names with catalysts and execution risk, without author entry intent.·
2026-06-30@Stockspy1-0.36Says FDMT squeeze appears to be on, implying bullish price pressure.·
2026-06-29@Stockspy1-0.33Sees real potential for significant short squeeze in FDMT.·
2026-06-29@Stockspy1-0.15Points to FDMT short ratio as notable positioning.·
2026-06-29@BiopharmIQ+0.35Biotech stock news list with percent moves and catalysts at open.·
2026-06-29@Stockspy1-0.21Chart observation of broad rounding base in FDMT.·
2026-06-29@Stockspy1-0.39Biotech breakout with minimum target of $17.50.·
2026-06-29@OzmosiHealth+0.304DMT completes enrollment for global Phase 3 wet AMD trial.·
2026-06-22@Quantumup1+0.00H.C. Wainwright reiterated OCUL Buy and raised PT to $25 from $21.·

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.